Despite clinical success, ESAs are generally administered when hemoglobin levels are < 10 g/dl owing to the risk for adverse effects. A 2009 study demonstrated that ESAs are associated with an increased risk for cardiovascular events, CKD progression, vascular access thrombosis, and overall mortality, particularly at higher doses.
Learn more about CKD anemia management.
Medscape © 2022 WebMD, LLC
Any views expressed above are the author's own and do not necessarily reflect the views of WebMD or Medscape.
Cite this: Pradeep Arora. Fast Five Quiz: Management of Chronic Kidney Disease Anemia - Medscape - Apr 19, 2022.